One of Europe's Largest and Most Experienced Life Sciences Investors

Neuravi, founded in 2009, has developed an innovative stroke treatment that significantly enhances patient outcomes by preserving abilities and saving lives.

The company’s flagship device, the EmboTrap, is specifically designed to efficiently remove clots from the brain—the primary cause of strokes—thereby facilitating recovery. In 2017 and just two years after receiving its initial investment by EQT Life Sciences, Neuravi was acquired by Johnson & Johnson. Today, EmboTrap devices are widely used to treat patients in both Europe and the United States.

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well-tolerated.

NewAmsterdam Pharma seeks to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor in patients at risk of cardiovascular disease, for whom existing therapies are not sufficiently effective or well-tolerated. Obicetrapib is also being investigated as a potential treatment for Alzheimer’s disease.

Onera Health is a Medtech/Digital Health company that has reimagined how sleep diagnosis can be performed. Current standard of care (a test called polysomnography or PSG), is expensive (it requires people, buildings and equipment), is inconvenient (it requires the patient to be assessed in a sleep clinic), and it has excessive waiting times that can be months or even years depending on where you live.

Based in the Netherlands, Onera has created a self applied, easy to use and wireless solution that generates the same quality and reliability of information as the standard of care, but from the comfort of the patient's own home. Faster access to sleep assessment allows patients to gain a diagnosis, and receive treatment much more quickly and in a more cost effective way.

PanTera is a Belgian company specializing in the production of actinium-225 (Ac-225), a promising alpha-emitting radioisotope used in targeted cancer therapies.

Established in 2022 as a joint venture between Ion Beam Applications (IBA) and the Belgian Nuclear Research Centre (SCK CEN), and since 2024 backed by EQT Life Sciences. PanTera aims to enhance the accessibility of innovative cancer treatments by ensuring a reliable supply of Ac-225.To achieve this, PanTera is constructing a state-of-the-art production facility in Mol, Belgium.

Their unique production process involves transforming radium-226 into high-purity Ac-225. This method emphasizes sustainability by recycling and reusing radium, reflecting the company's commitment to environmentally friendly practices.